BioCentury | Dec 20, 2019
Clinical News
Stealth cites endpoints in Phase III mitochondrial disease miss
...Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III...
...Total Fatigue Scores in the Phase III MMPOWER-3 trial. During an investor call on Monday, Stealth BioTherapeutics Corp....
...Story Hits $930M High Note” ). Lauren Martz, Associate Editor Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Alexion Pharmaceuticals Inc. Stealth BioTherapeutics Corp....
...Total Fatigue Scores in the Phase III MMPOWER-3 trial. During an investor call on Monday, Stealth BioTherapeutics Corp....
...Story Hits $930M High Note” ). Lauren Martz, Associate Editor Subcutaneous elamipretide (MTP-131, bendavia, ocuvia, ss-31) Alexion Pharmaceuticals Inc. Stealth BioTherapeutics Corp....